Text
Gardasil: The blueprint for BRIQ’s market potential
From lab breakthrough to global lifesaver, Gardasil transformed Queensland research into a pioneering cancer prevention strategy, setting a new benchmark for medical innovation.
Born in UQ laboratories, Gardasil—the world’s first cancer vaccine—stands as Australia’s greatest medical achievement. Developed by Prof Ian Frazer AC and Dr. Jian Zhou in the early 1990s and in-market since 2006, the groundbreaking HPV vaccine exemplifies the extraordinary commercial potential of research undertaken within BRIQ’s ecosystem. With 270 million doses administered across 130 countries and global sales exceeding US$58.8bn (2006–2024), Gardasil’s reach and impact are unparalleled. In 2012, its success catalysed the formation of the Translational Research Institute (TRI), which now leverages strategic international partnerships and pioneering translational frameworks to maintain market leadership. This remarkable journey illustrates how bold Australian innovation can produce worldwide health solutions with profound impact.
Articles Full
Case Studies
Link Boxes
